Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index within the range of \>= 25 and \<=45 kilograms per square meter (kg/m\^2)
MASH with fibrosis score of F3 or F4 confirmed by transient elastography measurement \>=12.0 kPa and \<=25.0 kPa
Agreement to adhere to the contraception requirements
You may not be if
Weight gain or loss \>5% in the 3 months prior to baseline or \>10% in the 6 months prior to baseline
Bariatric surgery within 1 year prior to baseline
Current signs or prior history of decompensated liver disease
Complications or clinical evidence of portal hypertension
Lack of peripheral venous access
Other causes of liver disease based on medical history and/or centralized review of liver histology
History of liver transplantation
Current or prior history of hepatocellular carcinoma (HCC)
Uncontrolled hypertension
Concomitant Type 1 diabetes, or Type 2 diabetes with HbA1c \>10%
History of malignancy within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
Current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening
Initiation of a medication of an antidiabetic, weight loss, lipid-modifying or anti-depressant drug class
Active tuberculosis requiring treatment within the 12 months prior to baseline
History of organ transplant
Clareo Health | A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
